We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

8 hedge funds and large institutions have $771K invested in Avenue Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

300% more funds holding

Funds holding: 2 → 8 (+6)

238% more capital invested

Capital invested by funds: $228K → $771K (+$543K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
8
Holders Change
+6
Holders Change %
+300%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$308K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$162K
3
BlackRock
BlackRock
New York
+$110K
4
BRWA
B. Riley Wealth Advisors
Florida
+$95.4K
5
SIM
Spark Investment Management
New York
+$80.8K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$73.4K
2
UBS Group
UBS Group
Switzerland
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
1
Millennium Management
New York
$258K +$308K +42 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$136K +$162K +22 New
BlackRock
3
BlackRock
New York
$91K +$110K +15 New
Goldman Sachs
4
Goldman Sachs
New York
$89K -$73.4K -10 -42%
BRWA
5
B. Riley Wealth Advisors
Florida
$83K +$95.4K +13 New
SIM
6
Spark Investment Management
New York
$69K +$80.8K +11 New
TRCT
7
Tower Research Capital (TRC)
New York
$41K +$51.4K +7 New
Morgan Stanley
8
Morgan Stanley
New York
$4K +$7.34K +1 New
UBS Group
9
UBS Group
Switzerland
– -$9K -1 Closed

ATXI Hedge Fund Activity: Q3 2017 in Review

8 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q3 2017, worth a combined $771K — up 238% from $228K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ATXI positions and 1 closed out — a net gain of 6 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $308K. The largest seller was Goldman Sachs, cutting an estimated $73.4K.

  • 8 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q3 2017, up from 2 in Q2 2017.
  • Funds reported $771K of Avenue Therapeutics, Inc. Common Stock stock for Q3 2017, up 238% quarter-over-quarter.
  • 7 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q3 2017 and 1 closed out, a net change of +6 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q3 2017 was Millennium Management, an estimated $308K added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q3 2017 was Goldman Sachs, an estimated $73.4K sold.

Based on aggregated 13F filings for Q3 2017.